The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
May 13th 2024
Antihemophilic factor (recombinant) Fc-VWF-XTEN fusion protein-ehtl was initally approved in February 2023 for adults and children with hemophilia A for prophylaxis and on-demand treatment to control bleeding.
Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
October 25th 2023Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Read More
Importance of Patient Navigation in Specialty Pharmacy
October 25th 2023Many patients face significant challenges in accessing their specialty medications, which highlights the importance of pharmacy-deployed patient navigation programs designed to help resolve nonclinical, system-related barriers to care.
Read More
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
October 25th 2023Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.
Read More
Novel Drug Combinations in Precision Medicine Are an Emerging Landscape for Pharmacists
A single-center experience at a tertiary medical center precision medicine clinic provides insight.
Read More
Study: No Difference Found in Safety of Reference Biologic, Biosimilar
October 9th 2023In the first systematic review using statistical methods, investigators found switching from a reference biologic to a biosimilar was comparable in safety, but no conclusion on immunogenicity could be drawn.
Read More
FDA Approves Nedosiran for Patients With Primary Hyperoxaluria Type 1
October 2nd 2023Nedosiran (Rivfloza; Novo Nordisk Inc) injection is designed to inhibit the expression of liver enzyme lactate dehydrogenases leading to oxalate overproduction in patients 9 years of age and older with PH1.
Read More